GAD2 and type 1 diabetes mellitus: Although promising in NOD mice, clinical trials focused on antigen-specific (insulin, GAD65) immunosuppression have failed to preserve insulin production in T1D patients, presumably because long-lasting tolerance to islet antigens was not induced [12, 13, 26].